Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BHST vs OBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OBIO Captures Overall Composite Edge (41.1 SELL vs 58.2 HOLD), While BHST Leads 5–1 on Growth & Valuation Pillars

OBIO Overall Winner 6-Pillar Tally: BHST 5 – 1 OBIO Matrix Metrics: BHST 6 – 2 OBIO

As of Nov 20, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (41.1/100 SELL vs. 58.2/100 HOLD) after splitting the core matrix 2–6 (led by Options & Positioning), while BHST wins 5–1 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus OBIO at $6.58 (N/M Forward P/E, -195.4% operating margin).

  • Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. OBIO 41.1/100 SELL), OBIO captures the overall institutional head-to-head verdict (2–6 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. -18.0% operating margin) and revenue trajectory (-89.4% vs. +3.8% YoY).
  • Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BHST vs OBIO
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58
OBIO NASDAQ Head-to-Head Winner
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.58
-6.0% 1D
Market Cap $550.9M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.18β · 88% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 55
RSI-14: 54.9 · SMA20: $6.19 · SMA50: $6.01

6-Pillar Scorecard Institutional Category Breakdown (BHST 5 – 1 OBIO)

Columns: Metric · BHST · OBIO
1. Valuation Multiples BHST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.7x 17.9x
2. Growth & Scale BHST
Revenue Growth (YoY) +3.8% -89.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $35M $31M
Market Cap $29.9M $550.9M
3. Profitability & Quality BHST
Gross Margin 59.0% 99.6%
Operating Margin -18.0% -195.4%
Net Profit Margin -31.2% -182.5%
Return on Equity (ROE) -142.5% -182.3%
4. Balance Sheet & Cash Flow BHST
Cash Generation (TTM) -$9.4M -$64M
Cash Flow Margin -26.6% N/A
Net Cash / Leverage $5.1M Net Cash $9.0M Net Debt (4.72x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 78.2% (21st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity 77.0% of Rev ($27M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Packaged Foods Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BHST (6) vs OBIO (2)
Institutional Metric BHST OBIO Criterion Row Edge
Market Capitalization
Scale
$29.9M $550.9M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+3.8% -89.4% Higher Growth BHST
Operating Margin (TTM)
Profitability
-18.0% -195.4% Higher Margin BHST
Net Profit Margin
Profitability
-31.2% -182.5% Higher Margin BHST
Return on Equity (ROE)
Capital Efficiency
-142.5% -182.3% Higher ROE BHST
52-Week Range Position
Momentum
6% ($1–$7) 72% ($3–$8) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
0.25β · 86% Vol 1.18β · 88% Vol Lower Realized Risk BHST
Unified Institutional Score
Composite Signal
58.2 / 100 (HOLD) 41.1 / 100 (SELL) Higher Composite BHST
Trailing 12M Revenue (USD)
Operating Scale
$35M $31M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
59.0% 99.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev N/M PEG · 17.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.4M ($5.1M Net Cash) -$64M ($9.0M Net Debt (4.72x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +42.91 pp
BHST: -22.62% · OBIO: +20.29%
3M Horizon OBIO +57.55 pp
BHST: -36.59% · OBIO: +20.96%
6M Horizon OBIO +128.39 pp
BHST: -66.32% · OBIO: +62.07%
1Y Horizon OBIO +120.6 pp
BHST: -79.4% · OBIO: +41.2%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BHST Revenue OBIO Revenue BHST Op. Margin OBIO Op. Margin Margin Leader
FY2022 N/A $0M N/A -924.3% OBIO
FY2023 $10M $0M -78.6% -1866.2% BHST
FY2024 $30M $0M -27.7% -2437.5% BHST
FY2025 $30M $30M -16.2% -154.7% BHST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OBIO CONSOLIDATION
36d in phase · OBV ACCUMULATION
Current IV 78.2%
IV Percentile 21st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $550.9M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BHST vs OBIO Key Questions & Quantitative Answers

As of Nov 20, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (41.1/100 SELL vs. 58.2/100 HOLD) after splitting the core matrix 2–6 (led by Options & Positioning), while BHST wins 5–1 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus OBIO at $6.58 (N/M Forward P/E, -195.4% operating margin). Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. OBIO 41.1/100 SELL), OBIO captures the overall institutional head-to-head verdict (2–6 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. -18.0% operating margin) and revenue trajectory (-89.4% vs. +3.8% YoY). Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BHST leads the Growth & Scale pillar: BHST posts +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin), compared with OBIO at -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), BHST cumulative revenue shifted +200.0% while OBIO shifted N/A. In operating R&D and SG&A reinvestment, BHST deploys 77.0% of Rev ($27M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OBIO.

BHST screens cheaper on headline valuation multiples. BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin), whereas OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHST (-142.5% ROE) versus OBIO (-182.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk). By comparison, OBIO carries 78.2% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.18β · 88% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.